Aim: To investigate the diagnostic performance of dedicated axillary hybrid F-2-[F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting axillary pathological complete response (pCR) following neoadjuvant systemic therapy (NST) in clinically node-positive breast cancer patients.
Materials And Methods: Ten prospectively included clinically node-positive breast cancer patients underwent dedicated axillary hybrid F-FDG PET/MRI after completing NST followed by axillary surgery. PET images were reviewed by a nuclear medicine physician and coronal T1-weighted and T2-weighted MRI images by a radiologist. All axillary lymph nodes visible on PET/MRI were matched with those removed during axillary surgery. Diagnostic performance parameters were calculated based on patient-by-patient and node-by-node validation with histopathology of the axillary surgical specimen as the reference standard.
Results: Six patients achieved axillary pCR at final histopathology. A total of 84 surgically harvested axillary lymph nodes were matched with axillary lymph nodes depicted on PET/MRI. Histopathological examination of the matched axillary lymph nodes resulted in 10 lymph nodes with residual axillary disease of which eight contained macrometastases and two micrometastases. The patient-by-patient analysis yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 25%, 100%, 100%, and 67%, respectively. The diagnostic performance parameters of the node-by-node analysis were 0%, 96%, 0%, and 88%, respectively. Excluding micrometastases from the node-by-node analysis increased the negative predictive value to 90%.
Conclusion: This pilot study suggests that the negative predictive value and sensitivity of dedicated axillary F-FDG PET/MRI are insufficiently accurate to detect axillary pCR or exclude residual axillary disease following NST in clinically node-positive breast cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.crad.2022.06.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benefits and harms of breast cancer screening revisited: a large, retrospective cross-sectional study quantifying treatment intensity in women with screen-detected versus non-screen-detected cancer in Australia and New Zealand.
BMJ Oncol
December 2023
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Objectives: Non-mortality benefits of breast cancer screening are rarely considered in assessments of benefits versus harms. This study aims to estimate the rate of overdiagnosis in women with screen-detected breast cancer (SDBC) by allocating cases to either possibly overdiagnosed (POD) or not overdiagnosed categories and to compare treatment recommendations for surgery and adjuvant treatments by category, age at diagnosis and cancer stage.
Methods And Analysis: Retrospective secondary analysis of 10 191 women diagnosed with breast cancer in Australia and New Zealand in 2018.
A risk prediction model for adult patients with difficult intravenous access.
J Vasc Access
January 2025
Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Background: The challenges posed by difficult intravenous access (DIVA) in clinical treatment are not only related to technical difficulties but also have the potential to affect the quality of patient care and overall experience. It is crucial to adopt effective strategies to address difficult intravenous access. Currently, the assessment of difficult veins largely relies on individual perception and experience, which introduces a significant degree of subjectivity.
View Article and Find Full Text PDFPerformance of sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node positive breast cancer patients: systematic review and meta-analysis.
Int J Surg
January 2025
Department of Surgery, American University of Beirut, Beirut, Lebanon.
Background: The reliability of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in patients with initially node-positive breast cancer is still controversial. This meta-analysis is conducted to investigate the feasibility and accuracy of SLNB after NACT in patients with initially positive axillary nodes.
Methods: We conducted a literature search using Medline, PubMed, Embase, Central, and SCOPUS up until April 2021 for studies on the performance of SLNB following NACT.
Application of Contrast-Enhanced Ultrasound Parameters of Metastatic Axillary Lymph Nodes in Breast Cancer Patients in Predicting the Efficacy of Neoadjuvant Chemotherapy in Early Stage.
J Clin Ultrasound
January 2025
Inpatient Department of Ultrasound, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Background: To investigate the performance of contrast-enhanced ultrasound(CEUS) parameters of metastatic axillary lymph nodes (ALNs) before and after two courses of neoadjuvant chemotherapy (NAC) in breast cancer patients in predicting the efficacy of NAC.
Methods: A total of 41 postoperative breast cancer patients were selected. All patients underwent NAC, and ALN biopsy was positive before chemotherapy.
Spontaneous regression in breast cancer is rare but can dramatically improve patient prognosis. Although the underlying mechanism is unknown, it may be due to a biological response to external invasion. An 81-year-old woman presented to our emergency department with a 600x100mm large breast mass.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!